N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive with the update released this week.
Share talk spoke with Nigel Theobald, covering the latest announcement and asking him about the market response to news being released by the company, current share price and how often do they have to update the markets?
Have you fully funded all current work streams in Q1/2 in 2022, yes we have more than sufficient funds to carry out the work planned, just a few of the topics raised in the podcast.
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
Listen On
Also Listen
-
Oracle Power (AIM:ORCP) Shareholder Q&A Q1 2024 - Zaks Traders Cafe
Zak Mir talks to Naheed Memon, CEO of Oracle Power, as she answers the latest qu -
Ondo Insurtech on track (LON: ONDO) CEO Craig Foster talks to Zaks Traders Cafe
Ondo InsurTech PLC (LON: ONDO), a pioneering firm in technology that mitigates -
Zak Mir interview with Jason Brewer, CEO of Marula Mining
Zak Mir talks to Jason Brewer, CEO of Marula Mining, regarding the latest develo -
Ryan Mee, CEO of Fulcrum Metals (AIM:FMET) latest interview with Zaks Traders Cafe
Zak Mir talks to Ryan Mee, CEO of Fulcrum Metals, as the company focused on mine